Auro Laboratories Limited Share Price

Equities

AUROLAB6

INE292C01011

Pharmaceuticals

Market Closed - Bombay S.E. 11:12:33 02/05/2024 BST 5-day change 1st Jan Change
253.4 INR +9.98% Intraday chart for Auro Laboratories Limited +24.64% +95.98%

Financials

Sales 2022 509M 6.1M 488M Sales 2023 529M 6.34M 507M Capitalization 341M 4.08M 327M
Net income 2022 28M 336K 26.85M Net income 2023 24M 288K 23.02M EV / Sales 2022 1.4 x
Net Debt 2022 85.66M 1.03M 82.15M Net Debt 2023 46.26M 555K 44.37M EV / Sales 2023 0.73 x
P/E ratio 2022
22 x
P/E ratio 2023
13.9 x
Employees 72
Yield 2022 *
-
Yield 2023
-
Free-Float 42.18%
More Fundamentals * Assessed data
Dynamic Chart
Auro Laboratories Limited Announces Cessation of Kailash Chand Bubna as Independent Director CI
Auro Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Auro Laboratories Limited Appoints Shaan Jain as Chief Financial Officer CI
Auro Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Auro Laboratories Limited Announces the Resignation of Amit Mahipat Shah as Chief Financial Officer, Effective October 1, 2023 CI
Auro Laboratories Limited Appoints Vishal Kailashchandra Jhunjhunwala as an Non-Executive & Independent Director CI
Auro Laboratories Plans to Spend INR400 Million to Expand Capacity of Metformin HCL Factory MT
Auro Laboratories Limited Announces Intimation Regarding Capacity Expansion CI
Auro Laboratories Limited Announces Resignation of Govardhan Das Agarwal as Director CI
Auro Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Auro Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Auro Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Auro Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Auro Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Auro Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022 CI
More news
1 day+9.98%
1 week+24.64%
Current month+57.24%
1 month+45.80%
3 months+86.53%
6 months+124.55%
Current year+95.98%
More quotes
1 week
195.00
Extreme 195
253.40
1 month
159.00
Extreme 159
253.40
Current year
121.30
Extreme 121.3
253.40
1 year
64.00
Extreme 64
253.40
3 years
52.50
Extreme 52.5
253.40
5 years
23.00
Extreme 23
253.40
10 years
5.23
Extreme 5.23
253.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 73 25/05/89
Compliance Officer - 30/05/22
Members of the board TitleAgeSince
Director/Board Member 45 31/07/99
Chief Executive Officer 73 25/05/89
Director/Board Member 59 26/03/15
More insiders
Date Price Change Volume
02/05/24 253.4 +9.98% 73 783
30/04/24 230.4 +7.66% 142,834
29/04/24 214 +0.80% 40,539
26/04/24 212.3 +5.91% 19,634
25/04/24 200.4 -0.74% 5,532

Delayed Quote Bombay S.E., May 02, 2024 at 11:12 am

More quotes
Auro Laboratories Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs), intermediates and generic formulations. The Company operates through the Pharmaceuticals segment. It offers APIs under categories, such as antihistamine, muscle relaxant, diuretic, iron deficiency, anti-diabetic, anti-fungal, anti-ulcer, iodine supplement, anti-malaria, analgesics, antacids anti-inflammatory and others. Its products under intermediates include Glibenclamde Sulphonamide, Cis-bramo benzoate, Cls-Tosylate, 2-Ethoxy Benzoic Acid, 3,4,5, Trimethoxy Benzoic Acid and 5-Bromo Phthalide. It also undertakes toll/custom manufacturing for APIs and Intermediates on contract basis. The Company has a presence in international markets with bulk of its production being exported to Southeast Asia, Middle East and several European Countries. Some of the countries it exports to are Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain and United Kingdom.
More about the company
  1. Stock Market
  2. Equities
  3. AUROLAB6 Stock